Market Research Report

A quick peek into the report

CRISPR Gene Editing Market - A Global and Regional Analysis

Focus on Product, Application, End User, and Country-Wise Analysis - Analysis and Forecast, 2020-2031

 
Some Faq's

Frequently Asked Questions

The global CRISPR gene editing market was valued at $1,088.6 million in 2020, and it is expected to reach $18,856.6 million by 2031, registering a CAGR of 29.60% during the forecast period.
The top market players are Abcam, Inc., Applied StemCell, Inc., Agilent Technologies, Inc., Cellecta, Inc., CRISPR Therapeutics AG, Thermo Fisher Scientific, Inc., GeneCopoeia, Inc., GenScript Biotech Corporation, Horizon Discovery Group PLC, Integrated DNA Technologies, Inc., Merck KGaA, New England Biolabs, Inc., Origene Technologies, Inc., Rockland Immunochemicals, Inc., Synthego Corporation, System Biosciences LLC, ToolGen, Inc., Takara Bio
Factors driving the growth of the CRISPR gene editing market are the prevalence of genetic disorders and the use of gene editing, government and private funding, and technology advancement in CRISPR gene editing.
Some of the main challenges restricting the growth of the CRISPR gene editing market are off-target effects and delivery and ethical concerns and implications with respect to human gene editing.
The potential opportunities that are likely to boost the growth of the CRISPR gene editing market are expanding gene and cell therapy areas and CRISPR gene editing scope in agriculture.
Similar Product

You may also like

Published Year: 2021

Global Cell and Gene Therapy Market: Focus on Product Type, Therapeutic Class, Pipeline, Regional an

The global cell and gene therapy market was valued at $2,599.7 million in 2020, and it is ...